Edwards Lifesciences Corp EW
We take great care to ensure that the data presented and summarized in this overview for Edwards Lifesciences Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EW
View all-
Vanguard Group Inc Valley Forge, PA53MShares$4.82 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY52.4MShares$4.77 Billion0.12% of portfolio
-
State Street Corp Boston, MA26.8MShares$2.44 Billion0.12% of portfolio
-
Brown Advisory Inc16.6MShares$1.52 Billion2.18% of portfolio
-
Alliancebernstein L.P. New York, NY16.4MShares$1.49 Billion0.57% of portfolio
-
Wellington Management Group LLP Boston, MA15.5MShares$1.42 Billion0.27% of portfolio
-
Geode Capital Management, LLC Boston, MA13.1MShares$1.19 Billion0.12% of portfolio
-
Jpmorgan Chase & CO New York, NY9.57MShares$872 Million0.08% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa7.63MShares$695 Million0.34% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.52MShares$594 Million0.08% of portfolio
Latest Institutional Activity in EW
Top Purchases
Top Sells
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Insider Transactions at EW
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 20
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,625
-7.85%
|
$489,375
$87.79 P/Share
|
Jun 20
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+13.45%
|
$253,125
$45.28 P/Share
|
Jun 20
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
535
-2.22%
|
$48,150
$90.0 P/Share
|
Jun 20
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
535
+2.18%
|
$24,075
$45.28 P/Share
|
Jun 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$435,000
$87.54 P/Share
|
Jun 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
May 30
2024
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Direct |
8,617
-11.22%
|
$749,679
$87.68 P/Share
|
May 21
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,625
-15.54%
|
$506,250
$90.45 P/Share
|
May 21
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+13.45%
|
$253,125
$45.28 P/Share
|
May 11
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,198
-3.77%
|
$103,028
$86.72 P/Share
|
May 11
2024
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,854
-3.58%
|
$245,444
$86.72 P/Share
|
May 11
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
814
-1.7%
|
$70,004
$86.72 P/Share
|
May 11
2024
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
821
-2.61%
|
$70,606
$86.72 P/Share
|
May 11
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
21
-0.01%
|
$1,806
$86.72 P/Share
|
May 11
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
377
-1.58%
|
$32,422
$86.72 P/Share
|
May 11
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-0.44%
|
$84,710
$86.72 P/Share
|
May 11
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
827
-1.07%
|
$71,122
$86.72 P/Share
|
May 11
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.32%
|
$19,694
$86.72 P/Share
|
May 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.48%
|
$435,000
$87.81 P/Share
|
May 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.66%
|
$225,000
$45.28 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 162K shares |
---|---|
Exercise of conversion of derivative security | 769K shares |
Bona fide gift | 429K shares |
Discretionary transaction | 2.56K shares |
Open market or private purchase | 580 shares |
Payment of exercise price or tax liability | 38.9K shares |
---|---|
Open market or private sale | 739K shares |
Bona fide gift | 429K shares |